Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Toxicol Pathol. 2016 Mar 18;44(5):738–748. doi: 10.1177/0192623316636717

TABLE 2.

Hepatic lesion prevalence. Percentages of individuals exhibiting a specific alteration calculated as the number of individuals with at least one occurrence of that alteration within a treatment.

Population ERSE Treatment Basophilic Foci (%) Clear Cell Foci (%) Mixed Foci (%) Adenomas (%) Microvesicular Vacuolation (%)
KC 0% (Control) 44 5.6 5.6 0 39
KC 0.1% 82 45 9.1 27 45
KC 1.0% 91 55 0 9.1 55
AW 0% (Control) 85 46 15 0 31
AW 0.1% 82 18 0 9.1 36
AW 1.0% 88 75 0 19 25